Harnessing the power of IFN for therapeutic approaches to COVID-19-Reference-Cited by-同舟云学术

Harnessing the power of IFN for therapeutic approaches to COVID-19

Published:2024-05-14 Issue:5 Volume:98 Page:
ISSN:0022-538X
Container-title:Journal of Virology
language:en
Short-container-title:J Virol

Author:

Viox Elise G.¹^ORCID,Bosinger Steven E.¹²³,Douek Daniel C.⁴,Schreiber Gideon⁵^ORCID,Paiardini Mirko¹³^ORCID

Affiliation:

1. Division of Microbiology and Immunology, Emory National Primate Research Center, Emory University, Atlanta, Georgia, USA

2. Emory NPRC Genomics Core Emory National Primate Research Center, Emory University, Atlanta, Georgia, USA

3. Department of Pathology and Laboratory Medicine, School of Medicine, Emory University, Atlanta, Georgia, USA

4. Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA

5. Department of Biomolecular Sciences, Weizmann Institute of Science, Rehovot, Israel

Abstract

ABSTRACT Interferons (IFNs) are essential for defense against viral infections but also drive recruitment of inflammatory cells to sites of infection, a key feature of severe COVID-19. Here, we explore the complexity of the IFN response in COVID-19, examine the effects of manipulating IFN on SARS-CoV-2 viral replication and pathogenesis, and highlight pre-clinical and clinical studies evaluating the therapeutic efficacy of IFN in limiting COVID-19 severity.

Funder

HHS | National Institutes of Health

Emory University

Fast Grants

William I. H. and Lula E. Pitts Foundation

Publisher

American Society for Microbiology

Link

https://journals.asm.org/doi/pdf/10.1128/jvi.01204-23

Reference131 articles.

1. TLR2 senses the SARS-CoV-2 envelope protein to produce inflammatory cytokines

2. SARS-CoV-2 Envelope (E) Protein Binds and Activates TLR2 Pathway: A Novel Molecular Target for COVID-19 Interventions

3. The Role of TLR2 in Infection and Immunity

4. Structural and functional properties of SARS-CoV-2 spike protein: potential antivirus drug development for COVID-19

5. SARS-CoV-2 spike protein interacts with and activates TLR41